Epidermal growth factor receptor (EGFR) has become the focus of targeted therapy for NSCLC due to its high mutation rate in the population, including exon 19 deletion (Del 19), exon 21 mutation (L858R), and T790M 2,3. Here, EGFR is linked to non-small cell lung carcinoma.